logo
Ice cream recall: Bars sold in 23 states including Alabama pose listeria risk

Ice cream recall: Bars sold in 23 states including Alabama pose listeria risk

Yahoo21-07-2025
More than 100,000 ice cream bars produced by Rich's Ice Cream, including ones sold in Alabama, have been recalled over concerns of potential listeria contamination.
The Food and Drug Administration Authority (FDA) announced July 17 that Florida-based Rich's Ice Cream Co. is recalling select products due to potential listeria monocytogenes contamination.
The recall, which impacts lot number 24351 through lot 25156 was initiated on June 27, according to the FDA notice and is classified as Class II with a total of 110,292 cases potentially affected. A Class II recall is "a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote," the FDA website states.
USA TODAY was unable to reach Rich's Ice Cream for comment on July 21.
Which Rich Ice Cream products are included in the recall? See list
The affected products, sold in multiple states, according to the FDA advisory, include:
Chocolate Crunch Cake Bars
Strawberry Shortcake Bars, Rich Bars
Crumbled Cookie Bars
Orange Cream Bars
Fudge Frenzy Bars
Cotton Candy Twirl Bars
Savagely Sour Blue Raspberry Bars
Savagely Sour Cherry Bars
Cool Watermelon Bars
The frozen treats were individually packaged in plastic bags and sold in master cases.
In Alabama: First Watch plans for dozens of new restaurants in 2025. Here's what to know in Alabama
Which states are impacted by the recall? See list
The affected products were distributed across 23 states, according to the FDA notice, including:
Arizona
Alabama
Ohio
California
Pennsylvania
Georgia
New York
New Jersey
Florida
Texas
Virginia
Illinois
Missouri
Massachusetts
Tennessee
Iowa
South Carolina
Oregon
Oklahoma
Nevada
Louisiana
Wisconsin
Nebraska
They were also sold in Nassau, the capital of The Bahamas.
More: Waffle House drops egg surcharge: Are egg prices going down? What to know in Alabama
What should you do if you purchased the affected products?
FDA and Rich Ice Cream Co. have not yet specified what remedies are available for customers. Rich Ice Cream Co. did not immediately reply to USA TODAY's request for a statement and more information on the recall.
Customers, meanwhile, can visit Rich Ice Cream Co.'s website for more information and to contact the company.
Listeria poisoning symptoms
Listeriosis, or listeria poisoning, is a foodborne bacterial infection most commonly caused by the bacterium listeria monocytogenes, according to the Centers for Disease Control and Prevention. It is considered a serious condition and can be dangerous or life-threatening, especially to older adults, people with weak immune systems, and pregnant women.
Listeria is the third leading cause of death from foodborne illness in the U.S., according to the CDC. The agency estimates that the disease impacts 1,600 Americans each year, with approximately 260 people dying from those infections.
Symptoms include, per the CDC:
Fever
Muscle aches
Headache
Stiff neck
Confusion
Loss of balance
Convulsions
Diarrhea
Other gastrointestinal symptoms
Miscarriage, stillbirth, premature delivery and/or life-threatening infection of newborn infants
Death
People in higher-risk categories who experience flu-like symptoms within two months after eating contaminated food should seek medical care.
Contributing: Natalie Neysa Alund, USA TODAY
Saman Shafiq is a trending news reporter for USA TODAY. Reach her at sshafiq@gannett.com and follow her on X and Instagram @saman_shafiq7.
This article originally appeared on USA TODAY: Rich's Ice Cream recalls 100,000 ice cream bars, including in Alabama
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Controversial FDA official Dr. Vinay Prasad departs agency
Controversial FDA official Dr. Vinay Prasad departs agency

CNN

timean hour ago

  • CNN

Controversial FDA official Dr. Vinay Prasad departs agency

Dr. Vinay Prasad, the controversial critic of the US Food and Drug Administration who took a top role at the regulatory agency in May, has resigned less than three months into the job. 'Dr. Prasad did not want to be a distraction to the great work of the FDA in the Trump administration and has decided to return to California and spend more time with his family,' a spokesperson for the US Department of Health and Human Services told CNN on Tuesday. Prasad, a hematologist oncologist, was named head of the FDA's Center for Biologics Evaluation and Research in early May, giving him purview over vaccines and biologic medicines. He was subsequently also given the role of FDA chief medical and scientific officer. Like a number of Trump administration health appointees, Prasad had been a harsh critic of the government's response and vaccine policies during the Covid-19 pandemic. Prasad's departure came amid fresh pressure from the White House for him to resign, according to a person familiar with the matter who was granted anonymity to describe the internal dynamics, and followed days of criticism from Laura Loomer, a right-wing activist with extraordinary access to President Donald Trump. Loomer had taken shots at him on her website and on social media, attacking him publicly for days as a 'progressive leftist saboteur' who was 'undermining President Trump's FDA.' Loomer focused on Prasad's previous social media posts and podcast episodes, where she said he aligned himself politically with liberal politicians and expressed 'disdain' for Trump. Her posts were followed by others from figures including former US Sen. Rick Santorum, who called Prasad 'the man destroying @POTUS legacy for helping patients,' and a Wall Street Journal opinion piece headlined, 'Vinay Prasad Is a Bernie Sanders Acolyte in MAHA Drag.' Prasad didn't respond to requests for comment. A White House spokesperson referred a request for comment to HHS. Prasad had been defended by FDA Commissioner Dr. Marty Makary just days ago; in an interview with Politico, Makary said Prasad is an 'impeccable scientist … one of the greatest scientific minds of our generation.' 'We thank him for his service and the many important reforms he was able to achieve in his time at FDA,' the spokesperson for HHS said. Prasad assumed his role at the FDA after years of being a vocal critic of some of the agency's drug approvals. In particular, he had railed against a decision to approve Sarepta's drug for Duchenne muscular dystrophy, Elevidys, arguing that there was little evidence it helped stall or reverse symptoms of the rare, fatal genetic disorder. This month, the FDA requested that Sarepta halt shipments of the drug after a reported death in a young patient in Brazil. Just one day before Prasad's departure, the agency made a surprising reversal and allowed Sarepta to resume shipments for certain patients. Prasad also drew criticism from former officials and vaccine experts after internal memos from May revealed that he overrode FDA scientists on recommendations for two new versions of Covid-19 vaccines. The then-CDER director rebuked recommendations for broad use of the shots; the FDA eventually approved the vaccines for use in older and immunocompromised people but did not advise them for younger Americans who don't have underlying conditions.

Controversial FDA official Dr. Vinay Prasad departs agency
Controversial FDA official Dr. Vinay Prasad departs agency

CNN

timean hour ago

  • CNN

Controversial FDA official Dr. Vinay Prasad departs agency

Dr. Vinay Prasad, the controversial critic of the US Food and Drug Administration who took a top role at the regulatory agency in May, has resigned less than three months into the job. 'Dr. Prasad did not want to be a distraction to the great work of the FDA in the Trump administration and has decided to return to California and spend more time with his family,' a spokesperson for the US Department of Health and Human Services told CNN on Tuesday. Prasad, a hematologist oncologist, was named head of the FDA's Center for Biologics Evaluation and Research in early May, giving him purview over vaccines and biologic medicines. He was subsequently also given the role of FDA chief medical and scientific officer. Like a number of Trump administration health appointees, Prasad had been a harsh critic of the government's response and vaccine policies during the Covid-19 pandemic. Prasad's departure came amid fresh pressure from the White House for him to resign, according to a person familiar with the matter who was granted anonymity to describe the internal dynamics, and followed days of criticism from Laura Loomer, a right-wing activist with extraordinary access to President Donald Trump. Loomer had taken shots at him on her website and on social media, attacking him publicly for days as a 'progressive leftist saboteur' who was 'undermining President Trump's FDA.' Loomer focused on Prasad's previous social media posts and podcast episodes, where she said he aligned himself politically with liberal politicians and expressed 'disdain' for Trump. Her posts were followed by others from figures including former US Sen. Rick Santorum, who called Prasad 'the man destroying @POTUS legacy for helping patients,' and a Wall Street Journal opinion piece headlined, 'Vinay Prasad Is a Bernie Sanders Acolyte in MAHA Drag.' Prasad didn't respond to requests for comment. A White House spokesperson referred a request for comment to HHS. Prasad had been defended by FDA Commissioner Dr. Marty Makary just days ago; in an interview with Politico, Makary said Prasad is an 'impeccable scientist … one of the greatest scientific minds of our generation.' 'We thank him for his service and the many important reforms he was able to achieve in his time at FDA,' the spokesperson for HHS said. Prasad assumed his role at the FDA after years of being a vocal critic of some of the agency's drug approvals. In particular, he had railed against a decision to approve Sarepta's drug for Duchenne muscular dystrophy, Elevidys, arguing that there was little evidence it helped stall or reverse symptoms of the rare, fatal genetic disorder. This month, the FDA requested that Sarepta halt shipments of the drug after a reported death in a young patient in Brazil. Just one day before Prasad's departure, the agency made a surprising reversal and allowed Sarepta to resume shipments for certain patients. Prasad also drew criticism from former officials and vaccine experts after internal memos from May revealed that he overrode FDA scientists on recommendations for two new versions of Covid-19 vaccines. The then-CDER director rebuked recommendations for broad use of the shots; the FDA eventually approved the vaccines for use in older and immunocompromised people but did not advise them for younger Americans who don't have underlying conditions.

U.S. FDA's chief medical and science officer Prasad departs agency
U.S. FDA's chief medical and science officer Prasad departs agency

CNBC

time2 hours ago

  • CNBC

U.S. FDA's chief medical and science officer Prasad departs agency

Vinay Prasad, the U.S. Food and Drug Administration's chief medical and science officer, has left the health regulator, the U.S. Department of Health and Human Services, which oversees the FDA, said on Tuesday, confirming an earlier news report. "Dr. Prasad did not want to be a distraction to the great work of the FDA in the Trump administration and has decided to return to California and spend more time with his family," an HHS spokesperson said in an emailed statement to Reuters. "We thank him for his service and the many important reforms he was able to achieve in his time at FDA." STAT News first reported about Prasad's departure, saying it came after a number of controversial decisions by the FDA regarding a gene therapy drug for the treatment of Duchenne muscular dystrophy manufactured by Sarepta Therapeutics. The agency first halted shipments of the drug, called Elevidys, after the deaths of some recipients but rescinded the suspension on Monday. In June, STAT News reported that Prasad was named as the health regulator's chief medical and science officer, citing an internal memo. In May, the FDA named Prasad, an oncologist who previously criticized FDA leadership and COVID-19 mandates, as the director of its Center for Biologics Evaluation and Research.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store